Pre-operative systemic (neo-adjuvant) therapy with trastuzumab and docetaxel for HER2-overexpressing stage II or III breast cancer: Results of a multicenter phase II trial

Annals of Oncology

Volumn 17, Issue 3, 2006, Pages 409-414

  Coudert, B P ^a,i   Arnould, L ^a   Moreau, L ^b   Chollet, P ^c   Weber, B ^d   Vanlemmens, L ^e   Molucon C ^a   Tubiana, N ^f   Causeret, S ^a   Misset, J L ^g   Feutray, S ^a   Mery Mignard, D ^h   Garnier, J ^g   Fumoleau, P ^a  

^a Department of Oncology   (France)

^b Clinique des Domes   (France)

^c CAC J Perrin   (France)

^d Department of Medical Oncology   (France)

^e Institut O Lambret   (France)

^f LIMOGES UNIVERSITY HOSPITAL   (France)

^g Hal St Louis ^*  (France)

^h SANOFI   (France)

ⁱ CENTRE GEORGES FRANÇOIS LECLERC   (France)

Author keywords

Breast cancer; Docetaxel; Efficacy; Neo adjuvant treatment; Safety; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GENE OVEREXPRESSION; HEART DISEASE; HISTOPATHOLOGY; HUMAN; INFECTION; LYMPH NODE DISSECTION; MASTECTOMY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; SKIN DISEASE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

EID: 33644683395     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdj096     Document Type: Article

References (26)

1. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst 2005; 97: 188-194.
2. Kurosumi M. Significance of histopathological evaluation in primary therapy for breast cancer-recent trends in primary modality with pathological complete response (pCR) as endpoint. Breast Cancer 2004; 11: 139-147.
3. King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erbB-related gene in a human mammary carcinoma. Science 1985; 229: 974-976.
4. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
5. Slamon DL, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
6. Marty M, Cognetti F, Maraninchi D et al. Efficacy and safety of trastuzumab combined with docetaxel in patients with HER2-positive metastatic breast cancer given as first-line treatment: Results of a randomized phase II trial (M77001). J Clin Oncol 2005; 23: 4265-4274.
7. Jones A, Leyland-Jones B. Optimizing treatment of HER2-positive metastatic breast cancer. Semin Oncol 2004; 31 (5 Suppl 10): 29-34.
8. Vincent-Salomon A, MacGrogan G, Couturier J et al. Calibration of immunohistochemistry for assessment of HER2 in breast cancer: Results of the French multicentre GEFPICS study. Histopathology 2003; 42: 337-347.
9. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
10. Sataloff DM, Mason BA, Prestipino AJ et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: A determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
11. Chevallier B, Roche H, Olivier JP et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate. Am J Clin Oncol 1993; 16: 223-228.
12. Marty M, Baselga J, Gatzemeier U et al. Pooled analysis of six trials of trastuzumab (Herceptin®): Exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate for clinical cardiac events. Breast Cancer Res Treat 2003; 82: S47 (Abstr 218).
13. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
14. Van Pelt AE, Mohsin S, Elledge RM et al. Neoadjuvant trastuzumab and docetaxel in breast cancer: Preliminary results. Clin Breast Cancer 2003; 4: 348-353.
15. Burstein HJ, Harris LN, Gelman R et al. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
16. Wenzel C, Hussain D, Bartsch R et al. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: A pilot study. J Cancer Res Clin Oncol 2004; 130: 400-404.
17. Buzdar AU, Ibrahim NK, Francis D et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin chemotherapy: Results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3656-3659.
18. Bines J, Murad A, Lago S et al. Multicenter Brazilian study of weekly docetaxel and trastuzumab as primary therapy in stage III, HER-2 overexpressing breast cancer. Proc Am Soc Clin Oncol 2003; 22: 67 (Abstr 268).
19. Schiffhauer LM, Griggs JJ, Ahrendt GM et al. Docetaxel and trastuzumab as primary systemic therapy for HER-2/neu-overexpressing breast cancer. Proc Am Soc Clin Oncol 2003; 22: 242 (Abstr 969).
20. Hurley J, Doliny P, Silva O et al. Neoadjuvant herceptin/taxotere/ cisplatin in the treatment of locally advanced and inflammatory breast cancer. Proc Am Soc Clin Oncol 2002; 21: 50a (Abstr 196).
21. Limentani SA, Brufsky AM, Erban JK et al. Dose dense neoadjuvant treatment of women with breast cancer utilizing docetaxel, vinorelbine and trastuzumab with growth factor support. Br Cancer Res Treat 2003; 82: S55 (Abstr 240).
22. Harris L, Burstein HJ, Gelman R et al. Preoperative trastuzumab and vinorelbine (HN) is a highly active, well-tolerated regimen for HER2 3+/ FISH+ Stage II/III breast cancer. Proc Am Soc Clin Oncol 2003; 22: 22 (Abstr 86).
23. Mehta SR Schubbert T, Hsiang D et al. High pathological complete remission rate following neoadjuvant taxane, carboplatin and trastuzumab therapy after doxorubicin and cyclophosphamide in Her-2 positive breast cancer patients. San Antonio Breast Cancer Symposium 2004. Abstract 1110.
24. Piccart-Gebhart MJ, Proctor M, Leyland-Jones B et al. Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005; 353: 1659-1672.
25. Perez EA. Further analysis of NCCTG-N9831. Oral presentation for late breaking. Scientific Symposium, Advances in Monoclonal Antibody Therapy for Breast Cancer. Proc Am Soc Clin Oncol 16 May 2005.
26. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer. N Engl J Med 2005; 353: 1673-1684.